ReviewPediatric nephrology (Berlin, Germany)2017
Biomarkers and targeted new therapies for IgA nephropathy.
Review in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2022Pooled it
- New prognostic markers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety.Clinical kidney journal · 2025Article
- Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model.Journal of the American Society of Nephrology : JASN · 2025Article
- Protocol for a systematic review of the application of the kidney failure risk equation and Oxford classification in estimating prognosis in IgA nephropathy.Systematic reviews · 2024Article
- Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children.Journal of clinical medicine · 2024Review
- Follicular Helper T Cells in Peyer's Patches and Galactose- Deficient Iga1 Contribute to Iga Nephropathy.Current molecular medicine · 2024Article
- Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.Kidney international reports · 2023Article
- Clinical manifestations and pathological correlation of immunoglobulin A nephropathy in children.BMC nephrology · 2022Article
- Chemokine (C-C motif) receptor 2 is associated with the pathological grade and inflammatory response in IgAN children.BMC nephrology · 2022Article
- Expression of CCL2, FOS, and JUN May Help to Distinguish Patients With IgA Nephropathy From Healthy Controls.Frontiers in physiology · 2022Article
- Non-immunosuppressive therapies for childhood IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2021Review
- Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.Journal of clinical medicine · 2021Review
- IgA vasculitis nephritis in children and adults: one or different entities?Pediatric nephrology (Berlin, Germany) · 2021Review
- Treatment of IgA nephropathy in children: a land without KDIGO guidance.Pediatric nephrology (Berlin, Germany) · 2021Review
- Emerging Modes of Treatment of IgA Nephropathy.International journal of molecular sciences · 2020Review
- Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy.Virchows Archiv : an international journal of pathology · 2020Article
- BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.Molecular medicine reports · 2020Article
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.Frontiers in immunology · 2020Review
- Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) has variable clinical presentation and outcome. There is a need to identify children who have the potential to progress to end stage renal disease (ESRD). Biomarkers related to the pathogenetic process of IgAN can detect risk factors and identify targets for new therapies. Galactose-deficient IgA1 (Gd-IgA1) is a specific biomarker of IgAN and could be the first treatment target. In experimental mice, reduction of IgA1 deposits and hematuria was observed after treatment with a bacterial protease that selectively cleaves human IgA1. Glycan-targeted drugs that may act to neutralize Gd-IgA1 inhibit abnormal enzymatic glycosylation of IgA1 or deplete cells producing Gd-IgA1. The autoimmune response to Gd-IgA1 produces autoantibodies that are sensitive and specific biomarkers of IgAN development and progression and suggests the possible benefits of anti-B cell therapies directed against CD20, B-cell activating factor (BAFF), or B cell receptor, and also proteasome inhibitors. The activation of complement in IgAN offers new biomarkers and the rationale for using complement inhibitors, including eculizumab. Renal pathological features represent sensitive biomarkers of added value over clinical data and may drive steroid therapy in selected cases. Finally, the hypothesis of the involvement of intestinal mucosal immunity in the pathogenesis of IgAN suggests the possibility of avoiding the systemic effect of steroid. Enteric budesonide targeting Peyer's patches at the ileocecal junction is an interesting option that has provided some preliminary favorable results in IgAN. In conclusion, the identification of new biomarkers is a promising area for therapies targeting IgAN in patients at risk of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.